Biography:David E. Olson
David E. Olson | |
|---|---|
| Nationality | American |
| Alma mater | Union College, Stanford University, Broad Institute of MIT and Harvard |
| Occupation | Chemical Neuroscientist, Professor, Entrepreneur |
| Employer | University of California, Davis; Delix Therapeutics |
| Known for | Discovery of neuroplasticity promoting effects of psychedelics |
| Website | Olsonlab.org |
David E. Olson, PhD is an American chemist and neuroscientist. He is an associate professor of chemistry, biochemistry and molecular medicine at the University of California, Davis.[1]
Olson is best known for his work investigating neuroplasticity promoting compounds, especially the potential of psychedelic drugs, including ketamine and serotonergic psychedelics, to alter brain structure and function. Olson also coined a term to refer to small molecules that are fast acting, durable neuroplasticity promoting compounds: psychoplastogens. Psychoplastogens are being developed to treat a wide variety of neuropsychiatric and neurodegenerative diseases, including depression, PTSD, and substance use disorders, among many others.[2][3]
Early life
Olson received his B.S. summa cum laude from Union College in 2006 with a major in chemistry and a minor in biology.[1]
He then worked briefly at Albany Molecular Research Inc. before completing a Ph.D. in chemistry at Stanford University[1] in 2011, where he worked in the laboratory of Justin Du Bois, developing a variety of methods for synthesizing nitrogen-containing compounds.[4]
Olson undertook postdoctoral research in neuroscience at the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard where he focused on the therapeutic potential of HDAC inhibitors.[5]
Career
In 2015 Olson started his independent career at the University of California, Davis with a joint appointment in the Department of Chemistry (College of Letters and Science) and the Department of Biochemistry and Molecular Medicine (School of Medicine).[1] He is also an affiliate member of the Center for Neuroscience and the UC Davis Memory and Plasticity Program.[6] In 2021, Olson was promoted to associate professor with tenure. In 2019, Olson co-founded Delix Therapeutics—a biotech company focused on developing novel neuroplasticity-promoting therapeutics for central nervous system diseases (CNS).[7] Olson served as the company's Chief Scientific Officer until 2021, when he transitioned to the roles of Chief Innovation Officer and Head of the Scientific Advisory Board.[8]
Other activities
Currently, he serves on the editorial advisory boards of the journals ACS Chemical Neuroscience[9] and ACS Pharmacology & Translational Science.[10]
Published works
Olson has published numerous scientific publications.[11] Several of his key contributions to the field are cited below:
- Dong, C.; Ly, C.; Dunlap, L. E.; Vargas, M. V.; Sun, J.; Hwang, I.-W.; Azinfar, A.; Oh, W. C.; Wetsel, W. C.; Olson, D. E.; Tian, L. Psychedelic-Inspired Drug Discovery Using an Engineered Biosensor. Cell, 2021, 184, 2779–2792.
- Cameron, L. P.; Tombari, R. J.; Lu, J.; Pell, A. J.; Hurley, Z. Q.; Ehinger, Y.; Vargas, M. V.; McCarroll, M. N.; Taylor, J. C.; Myers-Turnbull, D.; Liu, T.; Yaghoobi, B.; Laskowski, L. J.; Anderson, E. I.; Zhang, G.; Viswanathan, J.; Brown, B. M.; Tjia, M.; Dunlap, L. E.; Rabow, Z. T.; Fiehn, O.; Wulff, H.; McCorvy, J. D.; Lein, P. J.; Kokel, D.; Ron, D.; Peters, J.; Zuo, Y.; Olson, D. E. A Non-Hallucinogenic Psychedelic Analogue with Therapeutic Potential. Nature, 2021, 589, 474–479.
- Dunlap, L. E.; Azinfar, A.; Ly, C.; Cameron, L. P.; Viswanathan, J.; Tombari, R. J.; Myers-Turnbull, D.; Taylor, J. C.; Grodzki, A. C.; Lein, P. J.; Kokel, D.; Olson, D. E. Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogs Through Structure-Activity Relationship Studies. J. Med. Chem., 2020, 63, 1142–1155.
- Cameron, L. P.; Benson, C. J.; DeFelice, B. C.; Fiehn, O.; Olson, D. E. Chronic, Intermittent Microdoses of the Psychedelic N,N‐Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem. Neurosci., 2019, 10, 3261−3270.
- Ly, C.; Greb, A. C.; Cameron, L. P.; Wong, J.; Barragan, E.; Wilson, P.; Burbach, K. F.; Dunlap, L. E.; Soltanzadeh Zarandi, S.; Sood, A.; Duim, W. C.; Paddy, M. R.; Dennis, M.; McAllister, A. K.; Ori-McKenney, K. M.; Gray, J. A.; Olson, D. E. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018, 23, 3170–3182.
References
- ↑ 1.0 1.1 1.2 1.3 Marrush, Najwa (2017-07-27). "David E. Olson, Ph.D." (in en). https://neuroscience.ucdavis.edu/people/david-olson.
- ↑ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip" (in en). https://www.forbes.com/sites/willyakowicz/2021/10/01/delix-therapeutics-pursues-a-psychedelic-inspired-medicine-without-the-trip/.
- ↑ Smith, Dana G. (2022-07-15). "Opinion | Taking the Magic Out of Magic Mushrooms" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/2022/07/15/opinion/hallucinations-psychedelics-depression.html.
- ↑ Olson, David E.; Maruniak, Autumn; Malhotra, Sushant; Trost, Barry M.; Du Bois, J. (2011-07-01). "Synthesis and Reactivity of Unique Heterocyclic Structures en Route to Substituted Diamines" (in en). Organic Letters 13 (13): 3336–3339. doi:10.1021/ol2010769. ISSN 1523-7060. PMID 21618989.
- ↑ Olson, David E.; Sleiman, Sama F.; Bourassa, Megan W.; Wagner, Florence F.; Gale, Jennifer P.; Zhang, Yan-Ling; Ratan, Rajiv R.; Holson, Edward B. (2015-04-23). "Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism". Chemistry & Biology 22 (4): 439–445. doi:10.1016/j.chembiol.2015.03.014. ISSN 1879-1301. PMID 25892200. PMC 4562013. https://pubmed.ncbi.nlm.nih.gov/25892200/.
- ↑ "Leadership" (in en). http://memorygroup.ucdavis.edu/leadership.html.
- ↑ Yakowicz, Will. "Delix Therapeutics Pursues A Psychedelic-Inspired Medicine Without The Trip" (in en). https://www.forbes.com/sites/willyakowicz/2021/10/01/delix-therapeutics-pursues-a-psychedelic-inspired-medicine-without-the-trip/.
- ↑ LaHucik, Kyle (2021-09-27). "Delix raises $70M to test psychedelic analogs for treating brain disorders in clinical trials next year" (in en). https://www.fiercebiotech.com/biotech/delix-raises-70m-to-test-psychedelic-analogs-for-treating-brain-disorders-clinical-trials.
- ↑ "Editorial Board" (in en). https://pubs.acs.org/page/acncdm/editors.html.
- ↑ "Editorial Board" (in en). https://pubs.acs.org/page/aptsfn/editors.html.
- ↑ "My Bibliography - NCBI" (in en). https://www.ncbi.nlm.nih.gov/sites/myncbi/1ZGRv8OfBFrQ6/bibliography/50011637/public/?sort=date&direction=descending.
 |
